Raji A, et al. - Data were pooled from ten randomized, double-blind studies to evaluate the efficacy and safety profile of the dipeptidyl-peptidase-4 inhibitor sitagliptin in a population of self-identified Hispanic/Latino subjects with type 2 diabetes. For the purpose of this investigation, patients were treated with sitagliptin 100 mg/day (as mono- or combination therapy) or placebo and used to assess the glycemic efficacy, safety, and tolerability of sitagliptin compared with placebo after 24 weeks of treatment. It was observed that sitagliptin provided a significant improvement in glycemic control and was generally well tolerated in this pooled analysis of sitagliptin therapy vs placebo in Hispanic/Latino subjects.